10-Q: Simulations Plus Reports Mixed Results in Q2 2024, Revenue Growth Offset by Increased Costs

Simulations Plus saw a revenue increase in the second quarter of 2024, but this was offset by a significant rise in cost of revenues due to internal restructuring and the acquisition of Immunetrics.

Summary

• Simulations Plus reported a revenue increase of 16% to $18.3 million for the three months ended February 29, 2024, compared to $15.8 million for the same period in 2023.
• Software revenue increased by 11% and service revenue increased by 27% in the same period.
• The cost of revenues increased by 94% to $5.1 million, primarily due to internal restructuring and the acquisition of Immunetrics.
• Gross profit remained relatively flat at $13.2 million, with a decrease in gross margin from 83% to 72%.
• Net income decreased by 3% to $4.0 million, or $0.20 per share basic and diluted.
• For the six months ended February 29, 2024, revenue increased by 18% to $32.8 million compared to $27.7 million for the same period in 2023.
• The cost of revenues increased by 84% to $9.7 million for the six months ended February 29, 2024.
• Net income for the six months ended February 29, 2024, increased by 10% to $6.0 million, or $0.30 per share basic and $0.29 per share diluted.
• The company's cash and cash equivalents were $37.0 million, with $71.5 million in short-term investments and $9.0 million in long-term investments as of February 29, 2024.

Sentiment

Score: 5

Explanation: The document presents mixed results with strong revenue growth offset by a significant increase in costs, leading to a decrease in net income for the quarter. While the company has a strong cash position and is investing in growth, the increased costs and decreased margins are concerning. The sentiment is neutral to slightly negative.

Positives

• The company experienced strong revenue growth in both software and services segments.
• The company has a strong cash position with significant short-term and long-term investments.
• The company has a share repurchase program in place with $30 million remaining available.
• The company's reorganization is designed to optimize the utilization of scientific talent and improve operational performance.

Negatives

• The cost of revenues increased significantly, impacting gross profit and net income.
• Gross margin percentage decreased from 83% to 72% for the three months ended February 29, 2024.
• Net income decreased by 3% for the three months ended February 29, 2024.
• The reorganization of the company's internal structure led to a significant increase in cost of revenues.

Risks

• The company operates in a highly competitive and rapidly changing biosimulation market.
• Customer delays, holds, program cancellations, or consolidations in the pharmaceutical industry could adversely impact revenues and earnings.
• Economic uncertainty and changes in interest rates could negatively affect operations.
• The company's ability to develop new products and find new distribution channels could impact operating results.

Future Outlook

The company believes that its existing capital and anticipated funds from operations will be sufficient to meet its anticipated cash needs for working capital and capital expenditures for the foreseeable future, including the remaining $30 million of share repurchases. The company will continue to seek opportunities for strategic acquisitions, investments, and partnerships.

Management Comments

• The company reorganized its internal structure to move away from divisions based on prior acquisitions and instead form business units organized around key product and service offerings.
• The new business unit structure is designed to optimize the utilization of scientific talent in support of revenue growth objectives.
• Management believes that the need for improved productivity in the research and development activities directed toward developing new medicines will continue to result in increasing adoption of simulation and modeling tools and consulting services.

Industry Context

The biosimulation market is highly competitive and rapidly changing, with increasing adoption of simulation and modeling tools. The company's focus on AI/machine learning, physiologically based pharmacokinetics, and quantitative systems pharmacology/toxicology aligns with industry trends. Consolidation in the pharmaceutical industry could impact the company's revenues.

Comparison to Industry Standards

• Simulations Plus's revenue growth of 18% for the six months ended February 29, 2024, is strong compared to some of its peers in the biosimulation and pharmaceutical software space, but the increase in cost of revenues is a concern.
• Companies like Certara and Schrodinger, which also provide software and services for drug discovery and development, have reported varying growth rates and profitability, making a direct comparison challenging without specific financial details from those companies for the same period.
• The company's gross margin of 70% for the six months ended February 29, 2024, is lower than some software-focused companies in the industry, which often have higher margins due to lower cost of goods sold, but is typical for companies with a significant services component.
• The company's investment in R&D, with $1.8 million capitalized and $2.5 million expensed for the six months ended February 29, 2024, is consistent with industry standards for companies focused on innovation and product development.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and gross margin despite revenue growth.
• Employees may be impacted by the internal restructuring and changes in departmental structure.
• Customers may benefit from the company's continued investment in new products and services.
• Suppliers and creditors may be impacted by the company's financial performance and cash flow.

Next Steps

• The company will continue to seek opportunities for strategic acquisitions, investments, and partnerships.
• The company will continue to monitor the impact of economic conditions and industry trends on its operations.
• The company will continue to evaluate its departmental structure with a focus on improving operational performance and profitability.

Key Dates

Keywords

biosimulation, software, consulting services, pharmaceutical, revenue, cost of revenues, gross profit, net income, financial results, PBPK, QSP, AI, machine learning, drug development